A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.
In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.
Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer.
When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.
Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer therefore results in unnecessary biopsies and over-diagnosis and overtreatment of many men.
Circulating tumor cells
The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells, or circulating tumor cells (CTCs), that have left the original tumour and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient’s blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.
The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew’s Hospital in London.
The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.
When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 per cent accuracy, better than any previously reported biomarkers.
Additionally, the number and type of CTCs present in the blood was also indicative of the aggressiveness of the cancer. Focusing on more aggressive prostate cancer may reduce over-treatment and unnecessary biopsies for benign and non-aggressive conditions.
‘A paradigm shift in the way we diagnose prostate cancer’
Lead researcher Professor Yong-Jie Lu from Queen Mary’s Barts Cancer Institute said: “The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure.
“Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we’ve now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer.”
As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Prostate Cancer Tumor Size Often Underestimated by MRI, Study Findson January 21, 2021 at 2:59 pm
Magnetic resonance imaging (MRI) is often used in the diagnosis and management of prostate cancer, but the method frequently underestimates tumor size, a study in the Journal of Urology shows.
- AI-based technique may detect prostate cancer from urineon January 21, 2021 at 2:20 pm
Seoul, Jan 21 (IANS) A novel Artificial Intelligence (AI)-based technique may help in diagnosing prostate cancer from urine within only twenty minutes with almost 100 per cent accuracy, a new study ...
- This AI can tell if you have prostate cancer by looking at your peeon January 21, 2021 at 10:51 am
Researchers at the Korean Institute of Science and Technology (KIST) recently developed a machine for detecting prostate cancer that only needs 20 minutes of your time and a few ounces of your pee to ...
- Coffee Tied to Lower Risk of Prostate Canceron January 21, 2021 at 2:00 am
Drinking coffee may lower the risk for prostate cancer. Researchers combined data from 16 prospective studies that calculated the risk associated with the highest versus the lowest coffee consumption.
- New technique can rapidly diagnose prostate cancer from urineon January 20, 2021 at 11:25 pm
Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood.
- Prostate Cancer Diagnostics Market Statistics, Size, Share, Regional Analysis by Key Players | Industry Forecast to 2027on January 20, 2021 at 4:44 am
Rising incidences of prostate cancer is one of the significant factors influencing the growth of the diagnostic procedures for the disease. Market Size ...
- New tests may help improve the selection of men considering prostate cancer surveillanceon January 17, 2021 at 5:13 am
Sylvester Comprehensive Cancer Center researchers are looking at ways to combine imaging and biomarkers to predict prostate cancer progression more accurately.
- New clues to prostate canceron January 16, 2021 at 12:58 pm
New research has identified a new mechanism in which prostate cancer cells can 'switch' character and become resistant to therapy. These findings are an important development in unraveling how an ...
- Artificial intelligence tool for reading MRI scans could transform prostate cancer surgery and treatmenton January 15, 2021 at 6:17 am
Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict ...
- Coffee consumption associated with lower risk of prostate canceron January 14, 2021 at 10:33 am
According to a recent meta-analysis of existing studies, males who drink coffee daily may have a lower risk of prostate cancer compared with those who do not.
via Bing News